Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2016 Mar 30:6:23893.
doi: 10.1038/srep23893.

Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: evidence from 3,430 patients

Xiaobin Gu  1 , Shaoqian Sun  1 , Xian-Shu Gao  1 , Wei Xiong  2 , Shangbin Qin  1 , Xin Qi  1 , Mingwei Ma  1 , Xiaoying Li  1 , Dong Zhou  1 , Wen Wang  1 , Hao Yu  1
Affiliations
Meta-Analysis

Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: evidence from 3,430 patients

Xiaobin Gu et al. Sci Rep. .

Abstract

This study was designed to explore the association between elevated platelet to lymphocyte ratio (PLR) and prognosis of patients with non-small cell lung cancer (NSCLC) by meta-analysis. A total of 11 studies with 3,430 subjects were included and the combined hazard ratio (HR) and 95% confidence intervals (95% CI) were calculated. The data showed that elevated PLR predicted poor overall survival (OS) (HR = 1.42; 95% CI: 1.25-1.61, p < 0.001; I(2) = 63.6, Ph = 0.002) and poor disease-free survival (DFS)/progression-free survival (PFS) (HR = 1.19; 95%CI: 1.02-1.4, p = 0.027; I(2) = 46.8, Ph = 0.111). Subgroup analysis showed elevated PLR did not predict poor OS in patients included in large sample studies (HR = 1.44; 95% CI: 0.94-2.21, p = 0.098) whereas patients with Caucasian ethnicity (HR = 1.59; 95%CI: 1.27-1.98, p < 0.001) and PLR cut-off value > 180 (HR = 1.61; 95%CI: 1.3-1.99, p < 0.001) had enhanced prognostic efficiency for OS. Subgroup analysis also demonstrated that high PLR did not predict poor DFS/PFS in Asian patients. In conclusion, our meta-analysis suggested that elevated PLR was associated with poor OS and DFS/PFS in NSCLC. In addition, high PLR especially predicted poor OS in Caucasians but had no association with poor DFS/PFS in Asians.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Flow chart of the study selection.
Figure 2
Figure 2. Forest plot of the association between PLR and OS in patients with NSCLC.
Figure 3
Figure 3. Forest plot of the association between PLR and DFS/PFS in patients with NSCLC.
Figure 4
Figure 4
Sensitivity analysis on the relationship between PLR and (A) OS and (B) DFS/PFS in NSCLC.
Figure 5
Figure 5
Begg’s funnel plot of publication bias test for (A) OS and (B) DFS/PFS in NSCLC.
See this image and copyright information in PMC

References

    1. Torre L. A. et al. Global Cancer Statistics, 2012. CA-Cancer J. Clin. 65, 87–108, 10.3322/caac.21262 (2015). - DOI - PubMed
    1. Shepherd F. A. et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353, 123–132, 10.1056/NEJMoa050753 (2005). - DOI - PubMed
    1. Solomon B. J. et al. First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer. N. Engl. J. Med. 371, 2167–2177, 10.1056/NEJMoa1408440 (2014). - DOI - PubMed
    1. Heist R. S. & Engelman J. A. SnapShot: non-small cell lung cancer. Cancer Cell 21, 448.e442, 10.1016/j.ccr.2012.03.007 (2012). - DOI - PubMed
    1. Ettinger D. S. et al. Non-Small Cell Lung Cancer, Version 1.2015. J. Natl. Compr. Cancer Netw. 12, 1738–1761 (2014). - PubMed

Publication types